Tuesday 16 March 2010, 9:30 – 17:30 hrs

SESSION 1: OPENING SESSION - Chair: Charles Waller, PPTA

• Pandemic preparedness - Reinhard Burger, Robert Koch Institut
• State of the Industry - Larry Guiheen, Baxter
• FIND-ID: the role of immunodeficiency centres - Tim Niehues, Helios Kliniken Krefeld & Volker Wahn, Charité Berlin

SESSION 2: HEALTHCARE FUNDING - Chair: Julie Birkofer, PPTA

• The economic and fiscal consequences of ageing, with special focus on health and long term care - Bartosz Przywara, European Commission
• Global Observations: The View from The Top - Peter Turner, CSL Behring
• US Developments in Healthcare Reforms - Jay Greissing, PPTA
• Patient Perspective - Mark Skinner, World Federation of Hemophilia

SESSION 3: RARE DISEASES POLICIES – FROM THE EU TO THE MEMBER STATE - Chair: Rüdiger Gatermann, CSL Behring

• EMEA and Rare diseases - Rainer Seitz, EMEA
• FDA and Rare Diseases - Nisha Jain, FDA
• Impact of EU policies on Member States: The patient’s viewpoint, David Watters, Platform of Plasma Users (PLUS)
• National Healthcare Budgets and Rare Diseases - Rita Kessler, AIM
• Germany, Actions on Rare Diseases - Mirjam Mann, ACHSE

SESSION 4: REGULATION – CRITICAL CONSIDERATIONS - Chair: Reiner Seitz, Paul-Ehrlich-Institut

• Regulatory Leadership: Combating Regulatory Creep - Mary Gustafson, PPTA
• EDQM progress report towards international harmonization - Jean-Marc Spieser, EDQM
• Clinical Trials for Small Patient Populations - Thinking Outside the Box - Albert Farrugia, PPTA
• European Initiative for Better Regulation: Did it work? - Bernhard Lauven, Talecris
• How can science provide regulatory relief? - Herbert Dichtelmüller, Biotest

Wednesday 17 March 2010, 8:30 – 16:00 hrs

SESSION 5: BEYOND NORMAL SOURCE PLASMA - Chair: Kirsten Seidel, CSL Plasma

• Hyperimmunes: Demand and Supply - The Latest Developments - Patrick Robert, Marketing Research Bureau
• Collecting Hyperimmunes: Ethical and Regulatory Aspects - Ileana Carlisle, Biotest Pharmaceuticals
• Is Convalescent Plasma for Source Material a Viable Option to Manufacture H1N1 Immune Globulin? - Bill Bees, Cangene
• Collecting Plasma and Blood: A working model - Knud-Peter Krause, Haema AG
• Regulation: A Barrier to Self-Sufficiency - Michaela Rethwilm, Consultant

SESSION 6: EU SELF SUFFICIENCY – A DREAM? - Chair: Jan M Bult, PPTA

• Plasma Demand in 2015 - Patrick Robert, Marketing Research Bureau
• Plasma Procurement in Europe - Gerold Zerlauth, Baxter Bioscience
• Collecting Plasma and Blood; A Working Model - Knud-Peter Krause, Haema-AG
• Patient’s perspective - Brian O'Mahony, Irish Haemophilia Society

SESSION 7: THERAPY DEVELOPMENTS - Chair: Jacqueline Kerr, Paul-Ehrlich-Institut

• CIDP, focus on iG - John Winer, Queen Elizabeth Hospital Birmingham
• ITP, focus on iG - Thomas Kühne, University Children's Hospital Basel
• Albumin in Sepsis - Pietro Caironi, Istituto di Anestesiologia e Rianimazione, Milan